Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
What target volume and dose would you boost for inflammatory breast cancer with prepectoral saline implant?
Answer from: Radiation Oncologist at Community Practice
There is no defined boost volume and if has a poor response to chemo, would take tangential chest wall field to mid 50s dose.
Sign in or Register to read more
10571
Related Questions
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Would you feel comfortable doing high tangents with ultra-hypofractionation?
Is there any increased risk with adjuvant breast radiation for a patient with muscular dystrophy?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
In patients with history of prior axillary surgery, subsequently with breast cancer recurrence, and sentinel lymph nodes mapped to internal mammary area (but were not biopsied), do you offer post-mastectomy radiation to cover the IMNs?
How would you approach reirradiation in a patient with a history of whole-breast RT many years ago, now with a small intermediate-grade DCIS s/p lumpectomy with an elevated DCISionRT?
Under what circumstances would you pursue completion ALND in a patient with multiple positive sentinel nodes after breast-conserving surgery?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?